CN104360056B - A kind of method that promotes the sensitivity of latex enhancing immune turbidimetry - Google Patents
A kind of method that promotes the sensitivity of latex enhancing immune turbidimetry Download PDFInfo
- Publication number
- CN104360056B CN104360056B CN201410738145.1A CN201410738145A CN104360056B CN 104360056 B CN104360056 B CN 104360056B CN 201410738145 A CN201410738145 A CN 201410738145A CN 104360056 B CN104360056 B CN 104360056B
- Authority
- CN
- China
- Prior art keywords
- latex
- concentration
- sensitivity
- enhanced immune
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004816 latex Substances 0.000 title claims abstract description 68
- 229920000126 latex Polymers 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000035945 sensitivity Effects 0.000 title claims abstract description 29
- 238000004879 turbidimetry Methods 0.000 title claims abstract description 15
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 51
- 239000002245 particle Substances 0.000 claims abstract description 40
- 238000002835 absorbance Methods 0.000 claims abstract description 20
- 239000007853 buffer solution Substances 0.000 claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 18
- 230000008859 change Effects 0.000 claims abstract description 13
- 238000007817 turbidimetric assay Methods 0.000 claims abstract description 9
- 238000011088 calibration curve Methods 0.000 claims abstract description 6
- 239000011248 coating agent Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims abstract description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 48
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 19
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical group Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 239000008118 PEG 6000 Substances 0.000 claims description 12
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 12
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 12
- 239000003154 D dimer Substances 0.000 claims description 11
- 108010052295 fibrin fragment D Proteins 0.000 claims description 11
- 229930091371 Fructose Natural products 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- 239000005715 Fructose Substances 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 9
- 229940037003 alum Drugs 0.000 claims description 9
- 239000001177 diphosphate Substances 0.000 claims description 9
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 9
- 235000011180 diphosphates Nutrition 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 9
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 9
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 9
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 9
- 229940098773 bovine serum albumin Drugs 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000012491 analyte Substances 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000007789 sealing Methods 0.000 abstract description 2
- 238000004140 cleaning Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
- G01N33/546—Synthetic resin as water suspendable particles
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及体外诊断试剂领域,特别是涉及一种提升胶乳增强免疫比浊法灵敏度的方法。本发明提供一种提升胶乳增强免疫比浊法灵敏度的方法,包括如下步骤:1)选用大粒径的胶乳颗粒与抗体反应,进行抗体包被;2)将包被后的胶乳经过清洗和封闭步骤后,分散于缓冲液中,制得胶乳增强免疫比浊法试剂盒试剂2;3)配置胶乳增强免疫比浊法试剂盒试剂1;4)在全自动生化分析仪上,设置参数;5)运行生化仪,在使用已知浓度的样品进行定标后,检测待测样本得到吸光度变化值,根据校准曲线,计算出样本中待测物的含量。本发明所提供的提升胶乳增强免疫比浊法灵敏度的方法大大提升试剂的分析灵敏度和精密度,且并未提高检测成本,具有良好的应用前景。
The invention relates to the field of in vitro diagnostic reagents, in particular to a method for improving the sensitivity of latex-enhanced immune turbidimetry. The invention provides a method for improving the sensitivity of latex-enhanced immune turbidimetry, which includes the following steps: 1) selecting large-diameter latex particles to react with antibodies, and performing antibody coating; 2) cleaning and sealing the coated latex After the step, disperse in the buffer solution to prepare reagent 2 of the latex enhanced immune turbidimetric assay kit; 3) configure the reagent 1 of the latex enhanced immune turbidimetric assay kit; 4) set parameters on the automatic biochemical analyzer; 5 ) to run the biochemical analyzer, after calibration with a sample of known concentration, detect the sample to be tested to obtain the absorbance change value, and calculate the content of the sample to be tested according to the calibration curve. The method for improving the sensitivity of latex-enhanced immune turbidimetry provided by the present invention greatly improves the analytical sensitivity and precision of reagents without increasing the detection cost, and has good application prospects.
Description
技术领域technical field
本发明涉及体外诊断试剂领域,特别是涉及一种提升胶乳增强免疫比浊法灵敏度的方法。The invention relates to the field of in vitro diagnostic reagents, in particular to a method for improving the sensitivity of latex-enhanced immune turbidimetry.
背景技术Background technique
当光线通过一个浑浊介质溶液时,由于溶液中存在混浊颗粒,光线被吸收一部分,吸收的多少与混浊颗粒的量成正比,这种测定光吸收量的方法称为透射比浊法。这一方法早于1959年Schultre和Schuick等报道应用于血浆蛋白与其抗体结合后形成复合物,导致浊度的改变,再进行透射比浊测定,一般采用抗体对抗原定量的透射比浊法,称为免疫透射比浊法。其原理是,利用抗原和抗体的特异性结合形成复合物,通过测定复合物形成量的多少对抗原或抗体进行定量的方法。When light passes through a turbid medium solution, due to the presence of turbid particles in the solution, part of the light is absorbed, and the amount absorbed is proportional to the amount of turbid particles. This method of measuring light absorption is called turbidimetry. This method was earlier reported by Schultre and Schuick in 1959 and applied to the formation of complexes after the binding of plasma proteins and antibodies, resulting in changes in turbidity, and then the transmission turbidimetry. Generally, the transmission turbidimetry of antibody to antigen quantification is used, called For immunoturbidimetry. The principle is to use the specific combination of antigen and antibody to form a complex, and to quantify the antigen or antibody by measuring the amount of complex formation.
但是经典的免疫比浊法,少量的小的抗原抗体复合物极难形成浊度,除非放置较长时间;如形成较大的复合物,则抗原和抗体用量也较大,显然不符合微量化的要求。于是发展了现在广泛应用于生化分析仪的胶乳增强免疫比浊法(PETIA):以多克隆抗体为基础的改良免疫比浊分析法,利用基因工程方法将抗体与胶乳颗粒结合,当抗原抗体相结合时便形成了抗原-抗体-胶乳颗粒复合物,增强了反应吸光度,反应液在一定波长处比浊,与同样处理的标准液比较,计算标本中抗原的含量。利用生化分析仪进行比浊测定,整个分析过程只需几分钟,该方法与传统免疫比浊法比较其灵敏度更高。However, in the classic immunoturbidimetric method, a small amount of small antigen-antibody complexes is extremely difficult to form turbidity, unless it is left for a long time; if a larger complex is formed, the amount of antigen and antibody is also large, which obviously does not meet the requirement of microquantification. requirements. Therefore, the latex-enhanced immunoturbidimetric assay (PETIA), which is now widely used in biochemical analyzers, was developed: an improved immunoturbidimetric assay based on polyclonal antibodies, using genetic engineering methods to combine antibodies with latex particles. When combined, an antigen-antibody-latex particle complex is formed, which enhances the reaction absorbance. The reaction solution is turbidized at a certain wavelength, and compared with the same treated standard solution, the antigen content in the sample is calculated. Using a biochemical analyzer for turbidimetric determination, the entire analysis process only takes a few minutes. Compared with the traditional immunoturbidimetric method, this method has higher sensitivity.
随着检验医学的发展,对于低浓度检测物质的检测越来越多,检测物质的浓度正在从μg/mL级别下降至ng/mL级别,对于诊断试剂的灵敏度要求也越来越高,对于传统的胶乳增强免疫比浊法来说需要进一步的提升检测的灵敏度,以适应检测要求,传统的提升检测灵敏度的方法包括采用亲和力更高的抗体,采用更大颗粒,稳定性更好的胶乳颗粒,选用更好的促进抗原抗体反应的缓冲液体系等,但是这些都会增加试剂的成本,如何提升面对ng/mL级别被分析物的分析灵敏度和精密度,同时不增加成本一直是试剂开发的一大挑战。With the development of laboratory medicine, more and more low-concentration detection substances are detected, and the concentration of detection substances is decreasing from the μg/mL level to the ng/mL level. The sensitivity requirements for diagnostic reagents are also getting higher and higher. For traditional For the latex-enhanced immunoturbidimetric method, it is necessary to further improve the detection sensitivity to meet the detection requirements. The traditional methods to improve the detection sensitivity include using antibodies with higher affinity, using larger particles, and latex particles with better stability. Choose a better buffer system to promote the antigen-antibody reaction, but these will increase the cost of the reagent. How to improve the analytical sensitivity and precision of the analyte at the ng/mL level without increasing the cost has always been a part of reagent development. big challenge.
发明内容Contents of the invention
鉴于以上所述现有技术的缺点,本发明的目的在于通过反应波长的选择,不仅检测乳抗体抗原复合物的生成,还检测未结合胶乳颗粒的减少,提高检测物质的分析灵敏度和精密度,用于解决现有技术中的问题。In view of the shortcomings of the prior art described above, the purpose of the present invention is to not only detect the generation of milk antibody antigen complexes, but also detect the reduction of unbound latex particles through the selection of the reaction wavelength, so as to improve the analytical sensitivity and precision of the detected substances, It is used to solve the problems in the prior art.
为实现上述目的及其他相关目的,本发明第一方面提供一种提升胶乳增强免疫比浊法灵敏度的方法,包括如下步骤:In order to achieve the above purpose and other related purposes, the first aspect of the present invention provides a method for improving the sensitivity of latex-enhanced immune turbidimetry, comprising the following steps:
1)选用大粒径的胶乳颗粒与抗体反应,进行抗体包被,大粒径的胶乳颗粒的粒径为0.2-1.0μm;1) Select latex particles with a large particle size to react with the antibody for antibody coating. The particle size of the latex particles with a large particle size is 0.2-1.0 μm;
2)将包被后的胶乳经过清洗和封闭步骤后,分散于缓冲液中,制得胶乳增强免疫比浊法试剂盒试剂2;2) After the coated latex is washed and sealed, it is dispersed in the buffer solution to prepare the reagent 2 of the latex-enhanced immune turbidimetric assay kit;
3)配置有促进抗原和抗体反应作用的缓冲液,制得胶乳增强免疫比浊法试剂盒试剂1;3) A buffer solution for promoting the reaction of antigen and antibody is configured to prepare the reagent 1 of the latex-enhanced immune turbidimetric assay kit;
4)在全自动生化分析仪上,设置参数,其中,主波长设置为300-500nm,副波长设置为500-800nm,反应方向为负方向;4) On the fully automatic biochemical analyzer, set the parameters, wherein the main wavelength is set to 300-500nm, the secondary wavelength is set to 500-800nm, and the reaction direction is the negative direction;
5)运行生化仪,在使用已知浓度的样品进行定标后,检测待测样本得到吸光度变化值,根据校准曲线,计算出样本中待测物的含量。5) Run the biochemical analyzer, and after calibration with a sample of known concentration, detect the sample to be tested to obtain the absorbance change value, and calculate the content of the sample to be tested according to the calibration curve.
优选的,所述步骤2中,缓冲液为Tris-HCl缓冲液,浓度为50mM,其中牛血清白蛋白BSA的浓度为5g/L,叠氮钠的浓度为1g/L。Preferably, in the step 2, the buffer is Tris-HCl buffer with a concentration of 50 mM, wherein the concentration of bovine serum albumin (BSA) is 5 g/L, and the concentration of sodium azide is 1 g/L.
优选的,所述步骤3中,缓冲液为Tris-HCl缓冲液,其配方为:Tris50mmol/L,牛血清白蛋白BSA的浓度为3g/L,叠氮钠的浓度为1g/L,PEG6000的浓度为50g/L,水苏糖0.8-3g/L;明矾0.1-1g/L;果糖二磷酸钠0.8-3g/L;六偏磷酸钠0.05-0.5g/L,pH=7.0-7.4。Preferably, in the step 3, the buffer is Tris-HCl buffer, its formula is: Tris50mmol/L, the concentration of bovine serum albumin BSA is 3g/L, the concentration of sodium azide is 1g/L, the concentration of PEG6000 The concentration is 50g/L, stachyose 0.8-3g/L; alum 0.1-1g/L; sodium fructose diphosphate 0.8-3g/L; sodium hexametaphosphate 0.05-0.5g/L, pH=7.0-7.4.
优选的,所述提升胶乳增强免疫比浊法灵敏度的方法不是以疾病的诊断和治疗为目的的。Preferably, the method for improving the sensitivity of latex-enhanced immunoturbidimetry is not aimed at the diagnosis and treatment of diseases.
更优选的,对待测物含量的测量的直接目的不是获得诊断结果或健康状况,而只是从人体或动物体获取作为中间结果的信息的方法,或只是对已脱离人体或动物体的组织、体液或排泄物进行处理或检测以获取作为中间结果的信息的方法。More preferably, the direct purpose of measuring the content of the analyte is not to obtain diagnostic results or health conditions, but only to obtain information as an intermediate result from the human or animal body, or only to the tissues and body fluids that have been separated from the human or animal body. or excreta are processed or tested to obtain information as an intermediate result.
本发明第二方面提供所述提升胶乳增强免疫比浊法灵敏度的方法在生物检测领域的用途。The second aspect of the present invention provides the application of the method for improving the sensitivity of latex-enhanced immunoturbidimetry in the field of biological detection.
本发明第三方面提供一种高灵敏度胶乳增强免疫比浊法试剂盒,包括试剂1和试剂2,所述试剂2为包被有抗体的胶乳颗粒分散液,所述胶乳颗粒的粒径为0.2-1.0μm,所述试剂1为促进抗原和抗体反应的缓冲液。The third aspect of the present invention provides a high-sensitivity latex-enhanced immune turbidimetric assay kit, including reagent 1 and reagent 2, the reagent 2 is a dispersion of latex particles coated with antibodies, and the particle size of the latex particles is 0.2 -1.0 μm, the reagent 1 is a buffer to promote the reaction of antigen and antibody.
优选的,所述试剂1的配方为:Tris50mmol/L,牛血清白蛋白BSA的浓度为3g/L,叠氮钠的浓度为1g/L,PEG6000的浓度为50g/L,水苏糖0.8-3g/L;明矾0.1-1g/L;果糖二磷酸钠0.8-3g/L;六偏磷酸钠0.05-0.5g/L。Preferably, the formula of the reagent 1 is: Tris50mmol/L, the concentration of bovine serum albumin BSA is 3g/L, the concentration of sodium azide is 1g/L, the concentration of PEG6000 is 50g/L, stachyose 0.8- 3g/L; alum 0.1-1g/L; sodium fructose diphosphate 0.8-3g/L; sodium hexametaphosphate 0.05-0.5g/L.
优选的,所述试剂1中,pH值为中性。Preferably, in the reagent 1, the pH value is neutral.
优选的,所述试剂2中,包被的抗体与检测物相对应。Preferably, in the reagent 2, the coated antibody corresponds to the detection substance.
更优选为D-二聚体抗体。More preferred is a D-dimer antibody.
优选的,所述试剂2中,分散液中Tris-HCl缓冲液的浓度为50mM,牛血清白蛋白BSA的浓度为5g/L,叠氮钠的浓度为1g/L。Preferably, in the reagent 2, the concentration of Tris-HCl buffer in the dispersion is 50 mM, the concentration of bovine serum albumin BSA is 5 g/L, and the concentration of sodium azide is 1 g/L.
本发明第四方面提供所述高灵敏度胶乳增强免疫比浊法试剂盒的制备方法,包括如下步骤:The fourth aspect of the present invention provides the preparation method of the high-sensitivity latex-enhanced immune turbidimetric assay kit, comprising the following steps:
1.选用大粒径的胶乳颗粒与抗体反应,进行抗体包被,所述乳胶颗粒的粒径为0.2-1.0μm;1. Select latex particles with a large particle size to react with the antibody for antibody coating, and the particle size of the latex particles is 0.2-1.0 μm;
2.将包被后的胶乳经过清洗和封闭步骤后,分散于特定缓冲液中,制得胶乳增强免疫比浊法试剂盒试剂2;2. Disperse the coated latex in a specific buffer solution after washing and sealing steps to prepare reagent 2 of the latex-enhanced immune turbidimetric assay kit;
3.配置有促进抗原和抗体反应作用的缓冲液,制得胶乳增强免疫比浊法试剂盒试剂1。本发明第五方面提供所述高灵敏度胶乳增强免疫比浊法试剂盒在生物检测领域的用途。3. Prepare the reagent 1 of the latex-enhanced immune turbidimetric assay kit with a buffer solution for promoting the reaction of the antigen and the antibody. The fifth aspect of the present invention provides the use of the high-sensitivity latex-enhanced immunoturbidimetric assay kit in the field of biological detection.
本发明根据胶乳增强免疫比浊法的基本原理:即包被有抗体的胶乳与抗原反应,形成较大的胶乳抗原抗体复合物,引起浊度的增加,增强了反应吸光度,反应液在一定波长处测试,与同样处理的标准液比较,计算标本中抗原的含量。本发明人认为在包被抗体胶乳颗粒粒径较大的情况下,胶乳颗粒本身具有一定的浊度,在特定波长具有较大的吸收,而当包被抗体胶乳与抗原形成较大的胶乳抗原抗体复合物后,为反应的包被抗体胶乳颗粒也随之减少根据米氏散射理论,不同直径的微球对于固定波长的光反射能力不同,所以整个反应液在某些波长下吸光度增加,但是在某些波长下吸光度会下降,通过测量上升波长和下降波长的吸光度变化值,并进行加和,可以提升分析灵敏度的1倍以上。The present invention is based on the basic principle of latex-enhanced immune turbidimetry: that is, the latex coated with antibodies reacts with the antigen to form a larger latex-antigen-antibody complex, which causes an increase in turbidity and enhances the reaction absorbance. Test at the same place, compare with the standard solution treated in the same way, and calculate the antigen content in the specimen. The inventors believe that when the particle size of the coated antibody latex is large, the latex particle itself has a certain turbidity and has a large absorption at a specific wavelength, and when the coated antibody latex and the antigen form a larger latex antigen After the antibody complex, the unreacted coated antibody latex particles also decrease. According to the Mie scattering theory, microspheres with different diameters have different light reflection capabilities for fixed wavelengths, so the absorbance of the entire reaction solution increases at certain wavelengths, but The absorbance will decrease at certain wavelengths. By measuring the absorbance change values of the rising wavelength and the falling wavelength and summing them up, the analytical sensitivity can be increased by more than 1 times.
与现有技术相比,本发明具如下优势:Compared with the prior art, the present invention has the following advantages:
1.大大提升试剂的分析灵敏度和精密度:本发明发明人发现,通过特殊的促进抗原抗体反应的缓冲液,并进一步利用大粒径包被胶乳微球减少所引起的吸光度变化和胶乳抗原抗体复合物增加所引起的吸光度变化(大粒径包被胶乳微球减少所引起的吸光度变化往往大于胶乳抗原抗体复合物增加所引起的吸光度变化),两者吸光度变化加和后,试剂的分析灵敏度提升一倍或者以上,与此同时分析灵敏度的提升也带来精密度的提升。1. Greatly improve the analytical sensitivity and precision of reagents: the inventors of the present invention have found that through a special buffer solution that promotes the antigen-antibody reaction, and further utilize the large particle size coated latex microspheres to reduce the absorbance change and latex antigen-antibody The change in absorbance caused by the increase of the complex (the change in absorbance caused by the decrease of the latex microspheres coated with large particle size is often greater than the change in absorbance caused by the increase in the latex antigen-antibody complex), after the addition of the two absorbance changes, the analytical sensitivity of the reagent The increase is doubled or more, and at the same time, the increase in analytical sensitivity also brings about an increase in precision.
2.可以不增加或者是减少成本:首先本发明仅仅是测量方式的改变,可以很容易在全自动生化仪上通过修改参数的方式实现,所以不会增加成本,其次由于大粒径胶乳微球包被所需抗体往往比同质量的小粒径胶乳微球少(表面积较小),同时使用本发明所需的胶乳浓度较小,所以本发明往往可以减少试剂的成本。2. Can not increase or reduce cost: firstly, the present invention is only the change of the measurement method, which can be easily realized by modifying the parameters on the automatic biochemical analyzer, so the cost will not be increased; secondly, due to the large particle size latex microsphere The antibody required for coating is often less than the same amount of small-diameter latex microspheres (smaller surface area), and the concentration of latex required by the present invention is smaller, so the present invention can often reduce the cost of reagents.
附图说明Description of drawings
图1是实施例1制备的检测试剂盒的反应全波长扫描动力学实验结果。Fig. 1 is the reaction full-wavelength scanning kinetic experiment result of the detection kit prepared in Example 1.
图2是实施例1制备的检测试剂盒的校准曲线图。2 is a calibration curve diagram of the detection kit prepared in Example 1.
具体实施方式detailed description
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。Embodiments of the present invention are described below through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific implementation modes, and various modifications or changes can be made to the details in this specification based on different viewpoints and applications without departing from the spirit of the present invention.
在进一步描述本发明具体实施方式之前,应理解,本发明的保护范围不局限于下述特定的具体实施方案;还应当理解,本发明实施例中使用的术语是为了描述特定的具体实施方案,而不是为了限制本发明的保护范围;在本发明说明书和权利要求书中,除非文中另外明确指出,单数形式“一个”、“一”和“这个”包括复数形式。Before further describing the specific embodiments of the present invention, it should be understood that the protection scope of the present invention is not limited to the following specific specific embodiments; it should also be understood that the terms used in the examples of the present invention are to describe specific specific embodiments, It is not intended to limit the protection scope of the present invention; in the description and claims of the present invention, unless the context clearly indicates otherwise, the singular forms "a", "an" and "the" include plural forms.
当实施例给出数值范围时,应理解,除非本发明另有说明,每个数值范围的两个端点以及两个端点之间任何一个数值均可选用。除非另外定义,本发明中使用的所有技术和科学术语与本技术领域技术人员通常理解的意义相同。除实施例中使用的具体方法、设备、材料外,根据本技术领域的技术人员对现有技术的掌握及本发明的记载,还可以使用与本发明实施例中所述的方法、设备、材料相似或等同的现有技术的任何方法、设备和材料来实现本发明。When the examples give numerical ranges, it should be understood that unless otherwise specified in the present invention, the two endpoints of each numerical range and any value between the two endpoints can be selected. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to those skilled in the art's grasp of the prior art and the description of the present invention, the methods, equipment, and materials described in the embodiments of the present invention can also be used Any methods, apparatus and materials of the prior art similar or equivalent to the practice of the present invention.
除非另外说明,本发明中所公开的实验方法、检测方法、制备方法均采用本技术领域常规的分子生物学、生物化学、染色质结构和分析、分析化学、细胞培养、重组DNA技术及相关领域的常规技术。这些技术在现有文献中已有完善说明,具体可参见Sambrook等MOLECULARCLONING:ALABORATORYMANUAL,Secondedition,ColdSpringHarborLaboratoryPress,1989andThirdedition,2001;Ausubel等,CURRENTPROTOCOLSINMOLECULARBIOLOGY,JohnWiley&Sons,NewYork,1987andperiodicupdates;theseriesMETHODSINENZYMOLOGY,AcademicPress,SanDiego;Wolffe,CHROMATINSTRUCTUREANDFUNCTION,Thirdedition,AcademicPress,SanDiego,1998;METHODSINENZYMOLOGY,Vol.304,Chromatin(P.M.WassarmanandA.P.Wolffe,eds.),AcademicPress,SanDiego,1999;和METHODSINMOLECULARBIOLOGY,Vol.119,ChromatinProtocols(P.B.Becker,ed.)HumanaPress,Totowa,1999等。Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology and related fields in the technical field conventional technology.这些技术在现有文献中已有完善说明,具体可参见Sambrook等MOLECULARCLONING:ALABORATORYMANUAL,Secondedition,ColdSpringHarborLaboratoryPress,1989andThirdedition,2001;Ausubel等,CURRENTPROTOCOLSINMOLECULARBIOLOGY,JohnWiley&Sons,NewYork,1987andperiodicupdates;theseriesMETHODSINENZYMOLOGY,AcademicPress,SanDiego;Wolffe,CHROMATINSTRUCTUREANDFUNCTION, Thirdedition, Academic Press, San Diego, 1998; METHODSINENZYMOLOGY, Vol. 304, Chromatin (P.M. Wassarman and A.P. Wolffe, eds.), Academic Press, San Diego, 1999; and METHODSINMOLECULARBIOLOGY, Vol. Totowa, 1999 et al.
需要具体说明的是,本发明所用的原料基本均可以为市售产品,其中三羟甲基氨基甲烷Tris购自Sigma公司;其中羧基化聚苯乙烯胶乳颗粒以羧基化聚苯乙烯胶乳颗粒溶液的形式加入,购自日本JSR公司;D-二聚体抗体和D-二聚体购自芬兰hytest公司。It should be specified that the raw materials used in the present invention can be commercially available products substantially, wherein Tris is purchased from Sigma company; Added in the form, purchased from Japan JSR company; D-dimer antibody and D-dimer were purchased from Finland hytest company.
实施例1Example 1
一、定量检测胶乳增强免疫比浊试剂盒的制备1. Preparation of Quantitative Detection Latex Enhanced Immunoturbidimetric Kit
试剂1的制备:Preparation of Reagent 1:
由浓度为50mM的Tris-HCl缓冲液、3g牛血清白蛋白BSA、1g叠氮钠、2.2g水苏糖、0.6g明矾、1.9g果糖二磷酸钠、0.3g六偏磷酸钠和50gPEG6000制备得到,最终试剂1中Tris-HCl缓冲液的浓度为50mM,牛血清白蛋白BSA的浓度为3g/L,叠氮钠的浓度为1g/L,PEG6000的浓度为50g/L,水苏糖2.2g/L、明矾0.6g/L、果糖二磷酸钠1.9g/L、六偏磷酸钠0.3g/L;Prepared from Tris-HCl buffer solution with a concentration of 50mM, 3g bovine serum albumin BSA, 1g sodium azide, 2.2g stachyose, 0.6g alum, 1.9g sodium fructose diphosphate, 0.3g sodium hexametaphosphate and 50g PEG6000 , the concentration of Tris-HCl buffer in final reagent 1 is 50mM, the concentration of bovine serum albumin BSA is 3g/L, the concentration of sodium azide is 1g/L, the concentration of PEG6000 is 50g/L, stachyose 2.2g /L, alum 0.6g/L, sodium fructose diphosphate 1.9g/L, sodium hexametaphosphate 0.3g/L;
称取6.06g三羟甲基氨基甲烷(Tris)、3gBSA、50gPEG6000、水苏糖2.2g、明矾0.6g、果糖二磷酸钠1.9g、六偏磷酸钠0.3g、1g叠氮钠溶于0.8L去离子水中,用HCl调节pH至7.0,定容至1L即得试剂1。Weigh 6.06g of tris (Tris), 3g of BSA, 50g of PEG6000, 2.2g of stachyose, 0.6g of alum, 1.9g of sodium fructose diphosphate, 0.3g of sodium hexametaphosphate, and 1g of sodium azide in 0.8L In deionized water, adjust the pH to 7.0 with HCl, and dilute to 1 L to obtain reagent 1.
试剂2的制备:Preparation of Reagent 2:
由浓度为50mM的Tris-HCl缓冲液、5g的牛血清白蛋白BSA、1g的叠氮钠和包被鼠抗人D-二聚体抗体的致敏聚苯乙烯胶乳颗粒制备得到,最终试剂2中Tris-HCl缓冲液的浓度为50mM,牛血清白蛋白BSA的浓度为5g/L,叠氮钠的浓度为1g/L;Prepared from 50mM Tris-HCl buffer, 5g bovine serum albumin BSA, 1g sodium azide and sensitized polystyrene latex particles coated with mouse anti-human D-dimer antibody, final reagent 2 The concentration of Tris-HCl buffer in the medium is 50mM, the concentration of bovine serum albumin BSA is 5g/L, and the concentration of sodium azide is 1g/L;
①乳颗粒的活化、洗涤:①Activation and washing of milk particles:
取质量体积比为10%的羧基化聚苯乙烯胶乳颗粒溶液100μL,向其中加入质量浓度为1%EDAC溶液10μL,置于37℃摇床中反应0.5~1h后,再在12000rmp的转速下离心分离30min,然后倒掉上层清液,再用浓度为50mM、pH为7.2的甘氨酸缓冲液洗涤三次,最后将沉淀分散于1L浓度为50mM、pH为7.2的甘氨酸缓冲液中,使最终溶液中聚苯乙烯胶乳颗粒的浓度(以质量体积比计)为0.5~1%。Take 100 μL of carboxylated polystyrene latex particle solution with a mass volume ratio of 10%, add 10 μL of EDAC solution with a mass concentration of 1% to it, place it in a shaker at 37°C for 0.5 to 1 hour, and then centrifuge at a speed of 12000rmp Separation for 30 min, then discard the supernatant, wash three times with a glycine buffer solution with a concentration of 50 mM and a pH of 7.2, and finally disperse the precipitate in 1 L of a glycine buffer solution with a concentration of 50 mM and a pH of 7.2 to make the final solution aggregate The concentration of styrene latex particles (in terms of mass volume ratio) is 0.5-1%.
②抗体的纯化:② Antibody purification:
将鼠抗人D-二聚体抗体加入到透析袋中,在100mM、pH为7.2的PBS缓冲液中透析48小时,在透析的过程中换缓冲液3次,得到纯化的鼠抗人D-二聚体抗体。Add the mouse anti-human D-dimer antibody into the dialysis bag, dialyze in 100mM PBS buffer solution with pH 7.2 for 48 hours, change the buffer solution 3 times during the dialysis process, and obtain the purified mouse anti-human D-dimer antibody. Dimeric antibody.
③抗体胶乳颗粒的偶联:③ Coupling of antibody latex particles:
将经过步骤①活化后的羧基化聚苯乙烯胶乳颗粒溶液与步骤②纯化后的抗体混合,混匀后置于37℃摇床孵育2h,得到抗体-胶乳颗粒复合物;然后将抗体-胶乳颗粒复合物在12000rpm离心30min,倒掉上清液,再用浓度为100mM、pH为7.2的PBS缓冲液洗涤2次,最后再加入浓度为50mM、pH为7.0的Tris-HCl缓冲液10ml,搅拌混合均匀即可。其中10ml的Tris-HCl缓冲液中含有0.5mg的牛血清白蛋白BSA和1mg的叠氮钠;所述包被鼠抗人D-二聚体抗体的致敏聚苯乙烯胶乳颗粒的质量体积比终浓度为0.05~0.20%。Mix the carboxylated polystyrene latex particle solution activated in step ① with the antibody purified in step ②, mix well, and incubate on a shaker at 37°C for 2 hours to obtain the antibody-latex particle complex; then mix the antibody-latex particle The complex was centrifuged at 12000rpm for 30min, discarded the supernatant, washed twice with PBS buffer solution with a concentration of 100mM and a pH of 7.2, and finally added 10ml of a Tris-HCl buffer solution with a concentration of 50mM and a pH of 7.0, stirred and mixed Evenly. Wherein the Tris-HCl damping solution of 10ml contains the sodium azide of the bovine serum albumin BSA of 0.5mg and 1mg; The final concentration is 0.05-0.20%.
校准品的制备:Preparation of calibrator:
由浓度为100mM的PBS缓冲液、3g牛血清白蛋白BSA、1g叠氮钠和D-二聚体以制备得到,最终校准品中PBS缓冲液的浓度为100mM,牛血清白蛋白BSA的浓度为3g/L,叠氮钠的浓度为1g/L;It is prepared by PBS buffer solution with a concentration of 100mM, 3g bovine serum albumin BSA, 1g sodium azide and D-dimer, the concentration of PBS buffer solution in the final calibrator is 100mM, and the concentration of bovine serum albumin BSA is 3g/L, the concentration of sodium azide is 1g/L;
称取35.61Na2HPO4·2H2O、3g牛血清白蛋白BSA、1g叠氮钠溶于0.8L去离子水中,调节pH至7.2,用蒸馏水定容至1L,将D-二聚体溶于上述配制好的溶液中,配制成D-二聚体的浓度分别为0、0.5、1、2、4、8ng/mL的溶液,即得到校准品。Weigh 35.61Na 2 HPO 4 2H 2 O, 3g bovine serum albumin BSA, 1g sodium azide and dissolve in 0.8L deionized water, adjust the pH to 7.2, dilute to 1L with distilled water, dissolve D-dimer In the above-prepared solution, prepare solutions with D-dimer concentrations of 0, 0.5, 1, 2, 4, and 8 ng/mL, respectively, to obtain calibrator.
二、检测试剂盒的反应全波长扫描动力学实验2. The full-wavelength scanning kinetic experiment of the reaction of the detection kit
将校准品与试剂1混合均匀,37℃孵育5min后,加入试剂2,37℃孵育10S后使用紫外分光光度计全波长扫描反应液(第一次),37℃反应4min50S后使用紫外分光光度计全波长扫描反应液(第二次),计算吸光度变化值△A=A2-A1;全波长扫描的波长范围为200-800nm。表1所示为全波长扫描动力学实验结果。Mix the calibrator and reagent 1 evenly, incubate at 37°C for 5min, then add reagent 2, incubate at 37°C for 10S, use a UV spectrophotometer to scan the reaction solution at full wavelength (for the first time), react at 37°C for 4min for 50S, and use a UV spectrophotometer Scan the reaction solution at full wavelength (for the second time), and calculate the absorbance change value ΔA=A2-A1; the wavelength range of full-wavelength scanning is 200-800nm. Table 1 shows the experimental results of full-wavelength scanning kinetics.
表1Table 1
可以看到,反应液在340nm处的吸光度减少值,大于其在600nm处的吸光度增加值,如果将两个波长处的吸光度变化加和,可以大大提升试剂的分析灵敏度。It can be seen that the decrease in absorbance of the reaction solution at 340nm is greater than the increase in absorbance at 600nm. If the absorbance changes at the two wavelengths are added together, the analytical sensitivity of the reagent can be greatly improved.
三、定量检测胶乳增强免疫比浊试剂盒的使用方法3. Quantitative Detection of Latex Enhanced Immunoturbidimetric Kit
检测仪器:OLYMPUSAU640全自动生化分析仪Testing instrument: OLYMPUSAU640 automatic biochemical analyzer
根据本发明设置的参数为:检测方法:END.测定波长:主波长340nm,负波长600nm;样本量:25μL;试剂1:240μL;试剂2:80μL;校准方式:多点校准;反应方向:负。The parameters set according to the present invention are: detection method: END. measurement wavelength: main wavelength 340nm, negative wavelength 600nm; sample volume: 25μL; reagent 1: 240μL; reagent 2: 80μL; calibration method: multi-point calibration; .
试剂1的制备:Preparation of Reagent 1:
由浓度为50mM的Tris-HCl缓冲液、3g牛血清白蛋白BSA、1g叠氮钠、2.2g水苏糖、0.6g明矾、1.9g果糖二磷酸钠、0.3g六偏磷酸钠和50gPEG6000制备得到,最终试剂1中Tris-HCl缓冲液的浓度为50mM,牛血清白蛋白BSA的浓度为3g/L,叠氮钠的浓度为1g/L,PEG6000的浓度为50g/L,水苏糖2.2g/L、明矾0.6g/L、果糖二磷酸钠1.9g/L、六偏磷酸钠0.3g/L;Prepared from Tris-HCl buffer solution with a concentration of 50mM, 3g bovine serum albumin BSA, 1g sodium azide, 2.2g stachyose, 0.6g alum, 1.9g sodium fructose diphosphate, 0.3g sodium hexametaphosphate and 50g PEG6000 , the concentration of Tris-HCl buffer in final reagent 1 is 50mM, the concentration of bovine serum albumin BSA is 3g/L, the concentration of sodium azide is 1g/L, the concentration of PEG6000 is 50g/L, stachyose 2.2g /L, alum 0.6g/L, sodium fructose diphosphate 1.9g/L, sodium hexametaphosphate 0.3g/L;
称取6.06g三羟甲基氨基甲烷(Tris)、3gBSA、50gPEG6000、水苏糖2.2g、明矾0.6g、果糖二磷酸钠1.9g、六偏磷酸钠0.3g、1g叠氮钠溶于0.8L去离子水中,用HCl调节pH至7.0,定容至1L即得试剂1。Weigh 6.06g of tris (Tris), 3g of BSA, 50g of PEG6000, 2.2g of stachyose, 0.6g of alum, 1.9g of sodium fructose diphosphate, 0.3g of sodium hexametaphosphate, and 1g of sodium azide in 0.8L In deionized water, adjust the pH to 7.0 with HCl, and dilute to 1 L to obtain reagent 1.
试剂2的制备:Preparation of Reagent 2:
由浓度为50mM的Tris-HCl缓冲液、5g的牛血清白蛋白BSA、1g的叠氮钠和包被鼠抗人D-二聚体抗体的致敏聚苯乙烯胶乳颗粒制备得到,最终试剂2中Tris-HCl缓冲液的浓度为50mM,牛血清白蛋白BSA的浓度为5g/L,叠氮钠的浓度为1g/L;Prepared from 50mM Tris-HCl buffer, 5g bovine serum albumin BSA, 1g sodium azide and sensitized polystyrene latex particles coated with mouse anti-human D-dimer antibody, final reagent 2 The concentration of Tris-HCl buffer in the medium is 50mM, the concentration of bovine serum albumin BSA is 5g/L, and the concentration of sodium azide is 1g/L;
对比参数为:检测方法:END.测定波长:主波长600nm,负波长无;样本量:25μL;试剂1:240μL;试剂2:80μL;校准方式:多点校准;反应方向:正。The comparison parameters are: detection method: END. measurement wavelength: dominant wavelength 600nm, no negative wavelength; sample volume: 25 μL; reagent 1: 240 μL; reagent 2: 80 μL; calibration method: multi-point calibration; reaction direction: positive.
对比试剂1的制备:Preparation of comparative reagent 1:
由浓度为50mM的Tris-HCl缓冲液、3g牛血清白蛋白BSA、1g叠氮钠和50gPEG6000制备得到,最终试剂1中Tris-HCl缓冲液的浓度为50mM,牛血清白蛋白BSA的浓度为3g/L,叠氮钠的浓度为1g/L,PEG6000的浓度为50g/L;Prepared from Tris-HCl buffer with a concentration of 50mM, 3g bovine serum albumin BSA, 1g sodium azide and 50g PEG6000, the concentration of Tris-HCl buffer in final reagent 1 is 50mM, and the concentration of bovine serum albumin BSA is 3g /L, the concentration of sodium azide is 1g/L, and the concentration of PEG6000 is 50g/L;
称取6.06g三羟甲基氨基甲烷(Tris)、3gBSA、50gPEG6000、1g叠氮钠溶于0.8L去离子水中,用HCl调节pH至7.0,定容至1L即得试剂1。Weigh 6.06g of tris (Tris), 3g of BSA, 50g of PEG6000, 1g of sodium azide and dissolve in 0.8L of deionized water, adjust the pH to 7.0 with HCl, and dilute to 1L to obtain reagent 1.
试剂2与上述相同。Reagent 2 is the same as above.
将校准品与试剂1混合均匀,37℃孵育5min后,加入试剂2,37℃孵育10S后读取吸光度值A1,反应4min50S后读取吸光度值A2,计算吸光度变化值△A=A2-A1;然后以△A值为纵坐标,对应的校准品浓度为横坐标,绘制校准曲线,校准曲线如图2所示。Mix the calibrator and reagent 1 evenly, incubate at 37°C for 5 minutes, add reagent 2, incubate at 37°C for 10 seconds, read the absorbance value A1, and read the absorbance value A2 after reacting for 4 minutes and 50 seconds, and calculate the absorbance change value △A=A2-A1; Then take the △A value as the ordinate, and the corresponding concentration of the calibrator as the abscissa, and draw a calibration curve, as shown in Figure 2.
四、胶乳增强免疫比浊试剂盒的分析灵敏度和精密度对比实验4. Comparison experiment of analytical sensitivity and precision of latex-enhanced immunoturbidimetric kit
根据校准曲线,计算试剂的分析灵敏度结果见表2。表所示为本发明设置参数和对比参数的分析灵敏度。According to the calibration curve, the analytical sensitivity results of the calculated reagents are shown in Table 2. Table shows the analytical sensitivity of the present invention setting parameters and contrast parameters.
表2Table 2
精密度实验,采用高中低值样本重复测试10次,以测试结果的不精密度来表征试剂的精密度,结果看表3。In the precision experiment, the test was repeated 10 times with high, middle and low value samples, and the precision of the reagent was characterized by the imprecision of the test results. See Table 3 for the results.
表3table 3
本发明参数的试剂的分析灵敏度和精密度都明显优于对比参数,但是成本并没有增加。The analytical sensitivity and precision of the reagent with the parameter of the present invention are obviously better than those of the comparative parameter, but the cost does not increase.
综上所述,本发明有效克服了现有技术中的种种缺点而具高度产业利用价值。To sum up, the present invention effectively overcomes various shortcomings in the prior art and has high industrial application value.
上述实施例仅例示性说明本发明的原理及其功效,而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下,对上述实施例进行修饰或改变。因此,举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变,仍应由本发明的权利要求所涵盖。The above-mentioned embodiments only illustrate the principles and effects of the present invention, but are not intended to limit the present invention. Anyone skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or changes made by those skilled in the art without departing from the spirit and technical ideas disclosed in the present invention should still be covered by the claims of the present invention.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410738145.1A CN104360056B (en) | 2014-12-05 | 2014-12-05 | A kind of method that promotes the sensitivity of latex enhancing immune turbidimetry |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410738145.1A CN104360056B (en) | 2014-12-05 | 2014-12-05 | A kind of method that promotes the sensitivity of latex enhancing immune turbidimetry |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104360056A CN104360056A (en) | 2015-02-18 |
CN104360056B true CN104360056B (en) | 2016-05-04 |
Family
ID=52527337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410738145.1A Active CN104360056B (en) | 2014-12-05 | 2014-12-05 | A kind of method that promotes the sensitivity of latex enhancing immune turbidimetry |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104360056B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105510604A (en) * | 2016-02-01 | 2016-04-20 | 浙江夸克生物科技有限公司 | Method for improving sensitivity and linearity of latex reagent |
CN106053364A (en) * | 2016-05-26 | 2016-10-26 | 安徽伊普诺康生物技术股份有限公司 | Kit for measuring insulin and preparation method of kit |
CN110296944A (en) * | 2019-04-30 | 2019-10-01 | 宁波普瑞柏生物技术股份有限公司 | A method of improving immunoturbidimetry detection sensitivity and linear |
CN111190015B (en) * | 2019-10-18 | 2021-05-11 | 天津安百胜医疗科技有限公司 | Kit for detecting tetanus antibody in human plasma by latex enhanced immunoturbidimetry |
CN111323574A (en) * | 2020-02-26 | 2020-06-23 | 量准(上海)医疗器械有限公司 | Content determination method based on plasma optical nanopore enhanced immunoturbidimetry |
CN111830260B (en) * | 2020-07-27 | 2023-06-27 | 北京安图生物工程有限公司 | Process for reducing inter-batch difference in production of latex-enhanced immunoturbidimetry reagent |
CN111999506B (en) * | 2020-08-20 | 2023-03-31 | 安徽伊普诺康生物技术股份有限公司 | D-dimer detection kit and preparation method thereof |
CN112683820A (en) * | 2020-12-15 | 2021-04-20 | 量准(上海)医疗器械有限公司 | Detection method for latex immunoturbidimetry enhanced by plasma optical sensing chip |
CN114236116B (en) * | 2021-12-17 | 2024-10-01 | 武汉瀚海新酶生物科技有限公司 | Latex-enhanced immunoturbidimetry reagent and method for improving detection accuracy of latex-enhanced immunoturbidimetry reagent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102692507B (en) * | 2011-07-29 | 2015-09-16 | 南京诺尔曼生物技术有限公司 | Platelet-activating factor acetylhydro-lase (LPPLA2) measures kit (latex enhancing immune turbidimetry) |
CN103604931B (en) * | 2013-11-15 | 2016-01-06 | 陆上苏 | A kind of people's S100 protein assay reagent and preparation method |
CN104407154B (en) * | 2014-12-05 | 2016-03-30 | 重庆中元生物技术有限公司 | A kind of high sensitivity latex enhancing immune turbidimetry kit |
-
2014
- 2014-12-05 CN CN201410738145.1A patent/CN104360056B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN104360056A (en) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104360056B (en) | A kind of method that promotes the sensitivity of latex enhancing immune turbidimetry | |
CN104407154B (en) | A kind of high sensitivity latex enhancing immune turbidimetry kit | |
WO2013097606A1 (en) | Assay kit for neutrophil gelatinase-associated lipocalin | |
CN102227639B (en) | The assay method of the cysteine proteinase inhibitor C in human body fluid | |
CN104360081B (en) | Cystatin C detection kit of a kind of improvement and preparation method thereof | |
CN105842451B (en) | Method based on quantum dot fluorescence immune detection DNMT1 | |
CN101699287B (en) | Homogeneous phase sol particle type cystatin C measuring kit and preparation method thereof | |
CN103713134B (en) | A kind of detection kit of Visual retrieval virus and detection method thereof | |
CN111812336A (en) | Detection kit for detecting coronavirus antibodies and preparation method thereof | |
CN102636653A (en) | Compounded latex particle-enveloped cystatin C detection kit | |
CN103698535A (en) | Quantitative detection kit of lipoprotein associated phospholipase A2, as well as preparation and operation method of quantitative detection kit | |
CN104820090A (en) | Detecting kit for specific IgE antibody of food allergen as well as preparation and detecting methods of detecting kit | |
CN101210922A (en) | Colloidal gold-labeled protein A detects the method for the total amount of IgG in mammalian serum combined with the FC fragment of SPA | |
CN102586157A (en) | Method for enriching and capturing vibrio patahaemolyticus with high throughput | |
CN112730848A (en) | Kit and method for detecting retinol binding protein | |
WO2013146977A1 (en) | Immunological analysis method and reagent | |
CN106990234B (en) | A kind of detection reagent and method of lipoprotein (a) | |
JP7483168B2 (en) | Ferritin measurement reagent | |
CN105334317A (en) | Anti-LKM (liver-kidney microsomal) 1 antibody detection kit and detection method | |
CN101762703A (en) | Hepatitis C virus (HCV) antibody test kit, preparation method and detection method thereof | |
JP5085736B2 (en) | Method for measuring complex and kit used therefor | |
CN118777025A (en) | One-step quantitative detection method for CD3/GPRC5D bispecific antibody | |
CN106124773B (en) | IgM kit based on latex immunoturbidimetry and preparation method thereof | |
CN112763724A (en) | Reagent combination and kit for simultaneously determining content of retinol binding protein in serum and urine | |
CN107748254A (en) | A kind of N ends Natriuretic Peptide detection kit and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180105 Address after: 400000 Taikang Road Dadukou District of Chongqing Bridge Industrial Park C District No. 6 Building 30 layer 1-4 Patentee after: CHONGQING ZHONGYUAN HUIJI BIOTECHNOLOGY Co.,Ltd. Address before: Jiulongpo Branch Park four street 400039 Chongqing city 70-1, 70-2, J block three layer Patentee before: CHONGQING ZHONGYUAN BIOLOGICAL TECHNOLOGY CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Floor 1-4, building 30, no.6, Taikang Road, Zone C, Jianqiao Industrial Park, Dadukou District, Chongqing 400000 Patentee after: Zhongyuan Huiji Biotechnology Co.,Ltd. Address before: Floor 1-4, building 30, no.6, Taikang Road, Zone C, Jianqiao Industrial Park, Dadukou District, Chongqing 400000 Patentee before: CHONGQING ZHONGYUAN HUIJI BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 45 Shilin Avenue, Tiaodeng Town, Dadukou District, Chongqing 400082 Patentee after: Zhongyuan Huiji Biotechnology Co.,Ltd. Country or region after: China Address before: Floor 1-4, building 30, no.6, Taikang Road, Zone C, Jianqiao Industrial Park, Dadukou District, Chongqing 400000 Patentee before: Zhongyuan Huiji Biotechnology Co.,Ltd. Country or region before: China |